Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Wadie Messoudi, Toufik Elmahi, Chakib Nejjari, Nabil Tachfouti, Ahmed Zidouh, Ghali Saadani, David Moriña & Mireia Diaz. (2019) Cervical cancer prevention in Morocco: a model-based cost-effectiveness analysis. Journal of Medical Economics 22:11, pages 1153-1159.
Read now
Read now
Dimitris Kostaras, Eleftheria Karampli & Kostas Athanasakis. (2019) Vaccination against HPV virus: a systematic review of economic evaluation studies for developed countries. Expert Review of Pharmacoeconomics & Outcomes Research 19:2, pages 147-158.
Read now
Read now
Patricia R. Blank, Zanfina Ademi, Xiaoyan Lu, Thomas D. Szucs & Matthias Schwenkglenks. (2017) Herpes zoster vaccine: A health economic evaluation for Switzerland. Human Vaccines & Immunotherapeutics 13:7, pages 1495-1504.
Read now
Read now
Juan Luis Lopez-Belmonte, Ramón Cisterna, Angel Gil de Miguel, Caroline Guilmet, Florence Bianic & Mathieu Uhart. (2016) The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older. Journal of Medical Economics 19:6, pages 576-586.
Read now
Read now
Didik Setiawan, Jos Luttjeboer, Tjalke Arend Westra, Jan C Wilschut, Auliya A Suwantika, Toos Daemen, Jarir Atthobari, Bob Wilffert & Maarten J Postma. (2015) The cost–effectiveness of HPV vaccination in addition to screening: a Dutch perspective. Expert Review of Vaccines 14:4, pages 589-604.
Read now
Read now
Allex Jardim Fonseca & Luiz Carlos de Lima Ferreira. (2014) Systematic review of the cost-effectiveness of the vaccination against HPV in Brazil. Human Vaccines & Immunotherapeutics 10:12, pages 3484-3490.
Read now
Read now
Thomas D. Szucs, Reto W. Kressig, Manto Papageorgiou, Werner Kempf, Jean-Pierre Michel, Anton Fendl & Xavier Bresse. (2011) Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Human Vaccines 7:7, pages 749-756.
Read now
Read now
Birger Trollfors. (2008) Human papillomavirus vaccines: an outsider’s point of view. Expert Review of Vaccines 7:8, pages 1131-1133.
Read now
Read now
Articles from other publishers (24)
Thomas Szucs. (2021) Health Economics of Vaccination and Immunization Practices. VacciTUTOR.
Crossref
Crossref
André B. Kind, Andrew Pavelyev, Smita Kothari, Nadia El Mouaddin, Aurélie Schmidt, Edith Morais, Patrik Guggisberg & Florian Lienert. (2020) Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland. BMC Public Health 20:1.
Crossref
Crossref
Pierre Vassilakos, Antoine Poncet, Rosa Catarino, Manuela Viviano, Patrick Petignat & Christophe Combescure. (2019) Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland. Gynecologic Oncology 153:1, pages 92-99.
Crossref
Crossref
Andreas Chrysostomou, Dora Stylianou, Anastasia Constantinidou & Leondios Kostrikis. (2018) Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing. Viruses 10:12, pages 729.
Crossref
Crossref
Riccardo A. Audisio, Giancarlo Icardi, Andrea M. Isidori, Carlo A. Liverani, Alberto Lombardi, Luciano Mariani, Francesco Saverio Mennini, David A. Mitchell, Andrea Peracino, Sergio Pecorelli, Giovanni Rezza, Carlo Signorelli, Giovanni Vitali Rosati & Gian Vincenzo Zuccotti. (2016) Public health value of universal HPV vaccination. Critical Reviews in Oncology/Hematology 97, pages 157-167.
Crossref
Crossref
Paul L. McCormack. (2014) Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): A Review of Its Use in the Prevention of Premalignant Anogenital Lesions, Cervical and Anal Cancers, and Genital Warts. Drugs 74:11, pages 1253-1283.
Crossref
Crossref
Allex Jardim da Fonseca, Luiz Carlos de Lima Ferreira & Giacomo Balbinotto Neto. (2013) Cost-effectiveness of the vaccine against human papillomavirus in the Brazilian Amazon region. Revista da Associação Médica Brasileira 59:5, pages 442-451.
Crossref
Crossref
Zoltán Vokó, László Nagyjánosi & Zoltán Kaló. (2012) Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary. BMC Public Health 12:1.
Crossref
Crossref
Karen Canfell, Harrell Chesson, Shalini L. Kulasingam, Johannes Berkhof, Mireia Diaz & Jane J. Kim. (2012) Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries. Vaccine 30, pages F157-F167.
Crossref
Crossref
Adam J.N. Raymakers, Mohsen Sadatsafavi, Fawziah Marra & Carlo A. Marra. (2012) Economic and Humanistic Burden of External Genital Warts. PharmacoEconomics 30:1, pages 1-16.
Crossref
Crossref
Vernon J Lee, Sun Kuie Tay, Yee Leong Teoh & Mei Yin Tok. (2011) Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health 11:1.
Crossref
Crossref
Paul L. McCormack & Elmar A. Joura. (2011) Spotlight on Quadrivalent Human Papillomavirus(Types 6, 11, 16, 18) Recombinant Vaccine(Gardasil®) in the Prevention of PremalignantGenital Lesions, Genital Cancer, and Genital Warts in Women†. BioDrugs 25:5, pages 339-343.
Crossref
Crossref
C.D. Scarbrough Lefebvre, G. Van Kriekinge, M.A. Gonçalves & S. de Sanjose. (2011) Appraisal of the burden of genital warts from a healthcare and individual patient perspective. Public Health 125:7, pages 464-475.
Crossref
Crossref
Jean-Paul Fagot, Aurélie Boutrelle, Philippe Ricordeau, Alain Weill & Hubert Allemand. (2011) HPV vaccination in France: Uptake, costs and issues for the National Health Insurance. Vaccine 29:19, pages 3610-3616.
Crossref
Crossref
Giuseppe La Torre, Nicola Nicolotti, Chiara de Waure & Walter Ricciardi. (2010) Development of a weighted scale to assess the quality of cost-effectiveness studies and an application to the economic evaluations of tetravalent HPV vaccine. Journal of Public Health 19:2, pages 103-111.
Crossref
Crossref
Paul L. McCormack & Elmar A. Joura. (2010) Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®). Drugs 70:18, pages 2449-2474.
Crossref
Crossref
Patricia R Blank, Armin A Blank & Thomas D Szucs. (2010) Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema - a long-term analysis from a Swiss perspective. BMC Dermatology 10:1.
Crossref
Crossref
Mireia Diaz, Silvia de Sanjose, Jesse Ortendahl, Meredith O’Shea, Sue J. Goldie, F. Xavier Bosch & Jane J. Kim. (2010) Cost-effectiveness of human papillomavirus vaccination and screening in Spain. European Journal of Cancer 46:16, pages 2973-2985.
Crossref
Crossref
M. Obradovic, A. Mrhar & M. Kos. (2010) Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. The European Journal of Public Health 20:4, pages 415-421.
Crossref
Crossref
Philippe Beutels & Mark Jit. (2010) A brief history of economic evaluation for human papillomavirus vaccination policy. Sexual Health 7:3, pages 352.
Crossref
Crossref
Jaume Puig-Junoy & Beatriz G. Lopez-Valcarcel. (2009) Economic evaluations of massive HPV vaccination: Within-study and between study variations in incremental cost per QALY gained. Preventive Medicine 48:5, pages 444-448.
Crossref
Crossref
F.S. Mennini, P. Giorgi Rossi, F. Palazzo & N. Largeron. (2009) Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecologic Oncology 112:2, pages 370-376.
Crossref
Crossref
Thomas D. Szucs & Konstantin J. Dedes. 2009. Cancer Prevention II. Cancer Prevention II
41
47
.
. (2013) Betting Swiss gold on HPV vaccination. PharmacoEconomics & Outcomes News 554:1, pages 7-7.
Crossref
Crossref